Alterity Therapeutics Limited reported a positive End-of-Phase 2 meeting with the FDA, establishing a registrational pathway for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support approval. The company plans to initiate this Phase 3 trial by year-end 2026, enrolling approximately 200 patients randomized 1:1 to ATH434 or placebo for 12 months. Alterity completed a 1-for-50 share consolidation on May 29, 2026, and appointed Ann Cunningham to its Board in April 2026. As of June 30, 2026, the company held A$37.3 million in cash after receiving an A$3.98 million R&D tax refund subsequent to quarter-end. Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases.

Alterity Therapeutics Limited filed a 6-K containing an application for quotation of securities under the ticker symbol ATH. The company is a development stage enterprise. Alterity Therapeutics Limited is a biotechnology company focused on therapeutic development.

Alterity Therapeutics Limited submitted a corporate presentation dated June 2026 as an exhibit to this 6-K filing. The company is a development stage enterprise. Alterity Therapeutics is a biotechnology company focused on developing therapeutics for neurological diseases.